Summary of Changchun High-tech Conference Call Company Overview - **Company**: Changchun High-tech - **Date**: October 30, 2025 Key Points Financial Performance - **Overall Revenue**: Approximately 9.8 billion RMB, with a profit of about 1.165 billion RMB [3] - **Jinsai Pharmaceutical**: Revenue remained stable at 8.213 billion RMB, profit down by approximately 50% [3] - **Baike Pharmaceutical**: Revenue impacted by the return of shingles vaccine, down 53% to about 474 million RMB, resulting in a loss of approximately 158 million RMB [2][3] - **Traditional Chinese Medicine Segment**: Revenue slightly decreased to 542 million RMB, but profit increased by 2% to 36 million RMB [3] - **Real Estate Segment**: Revenue decreased by 8% to 544 million RMB, maintaining a slight profit [3] Product Pipeline and Market Strategy - **Medicare National Negotiation Participation**: Products include long-acting growth hormone Jinsai Zeng, Meishiya, and Children's Golden Granules, with decisions based on pricing [2][5] - **Innovative Drug Pipeline**: Products like NK422 and NK27 have shown preliminary clinical data, with expectations for rapid growth in business development (BD) from 2026 to 2028 [2][6] - **Sales Performance of New Products**: Strong sales momentum for Fuxing Umbilical Monoclonal Antibody, Meishiya, and Children's Golden Granules [2][6] - **Allergy Treatment Collaboration**: Partnership with LK for dust mite desensitization treatment, with plans to establish allergy desensitization centers in major pediatric hospitals [2][7] Clinical Trials and Development - **PD-1 Agonist**: Currently in Phase I clinical trials, with plans for Phase II trials following data disclosure [13] - **Clinical Progress of Meishiya**: Used for cancer anorexia and cachexia treatment, currently enrolling for clinical trials [11] - **Growth Hormone Monthly Formulation**: Adult SAD trials progressing well, transitioning to pediatric CAD trials expected soon [11] Market Challenges and Opportunities - **Non-Entry into Medicare for Jinsai Zeng**: Decision based on anticipated unreasonable pricing from the government; plans to negotiate with commercial insurance [12][14] - **Sales Team Expansion**: Sales team has grown to over 200 members, aiming to cover more than 1,500 hospitals [10][17] - **Focus on Respiratory and Allergy Treatments**: Targeting major diseases like cystic fibrosis and chronic obstructive pulmonary disease (COPD) with innovative products [19] Future Outlook - **Growth Potential**: Despite short-term challenges, long-term growth potential remains strong, especially in innovative drug development and market expansion [21][24] - **Hong Kong Listing Progress**: Normal progress with documents submitted by September 30, aiming for successful issuance next year [22] - **Clinical Pipeline**: 41 clinical pipelines in development, focusing on maximizing potential through continuous R&D [25] Additional Insights - **Market Size for Allergy Treatments**: Approximately 20 million children in China suffer from moderate to severe allergic rhinitis, providing a substantial market opportunity [8] - **Sales Strategy**: Emphasis on professional promotion and market penetration to enhance product visibility and acceptance among healthcare providers [18] This summary encapsulates the key insights from the conference call, highlighting the financial performance, product pipeline, market strategies, and future outlook of Changchun High-tech.

2025年10月23日，在厦门举办的"创新引领，成长无界"儿科多领域研发与儿童健康管理研讨会上，长春高新（000661）(000661.SZ)子公司金赛药业创始人、 首席科学家兼总经理金磊博士发表了题为《聚焦儿科，持续创新》的主题演讲，引发儿科医疗界的广泛关注。演讲不仅展示了金赛药业在儿童健康领域的最 新研发成果，系统阐释了公司从"生长激素单核驱动"向"儿童健康平台型企业"的战略转型路径，也成为金赛持续研发与锐意创新的有力见证。 金赛药业创始人、首席科学家兼总经理金磊博士 十年铸就高质量长效生长激素：从"剂型创新"到"标准制定" 2014年，金赛药业上市了全球首款长效生长激素，将治疗从每日注射推进至每周一次的新阶段。上市十年来，金赛持续投入，全面提升全产业链能力，着力 突破工艺复杂性、质量均一性和规模化稳定性三大质控难关。例如，公司建成国际规模领先的中试和生产基地，确保PEG达到全球最高纯度；持续改进工 艺，首创集成化检测体系，构建杂质全谱识别能力，并创新引入分子排阻层析作为吸附层析的补充。仅此一步，就使每批生长激素收率损失20%，2015至 2025年间直接成本投入达3亿元人民币。 纯度和工艺的不断精进，为 ...